Facebook agreed to compensate $52 million to its content moderators who developed PTSD and other mental health issues on the job. Yahoo Finance’s On The Move panel breaks down the latest developments. ...
The Federal Motor Carrier Safety Administration has expanded through June 14 its emergency declaration relaxing hours-of-service and some other rules for drivers transporting “relief” loads for COVID-19. ...
The Stifel strategist who predicted April’s market rally says the best strategy right now is to be like the Road Runner: “Step out of the way and let anvil hit Wile E. Coyote — the economy. And then after that, the Fed will act and then you can move on, if you're the investor.”...
Despite the pandemic risk, one analyst at Morgan Stanley remains bullish on AbbVie Inc (NYSE: ABBV).The AbbVie Analyst David Risinger maintained an Overweight on AbbVie with a $95 price target. The AbbVie Thesis Risks to U.S. sales stemming from unemployment and the Humira patent cliff are likely to be pushbacks for AbbVie, Risinger said in a Wednesday note. (See his track record here.)AbbVie's U.S. commercial exposure is at 42% of global sales compared to Eli Lilly And Co's (NYSE: LLY) 30%, the analyst said. Notwithstanding the pushback, he said he sees AbbVie stock's valuation and yield as attractive. Though Risinger said he is cognizant of the patent cliff faced by AbbVie's rheumatoid arthritis drug Humira, he chooses to focus beyond that issue. Below-consensus sales of Humira in the 2023-24 period will be offset by higher excluding-Humira sales, the analyst said. Risinger sees the gentlest cliff for AbbVie. He estimates that 45%...
On Wednesday, Jerome Powell shared prepared remarks regarding the future outlook for the U.S. economy, but admits there are 'longer-term concerns.' Andrew Slimmon, Morgan Stanley Investment Management Managing Director and Sr. Portfolio Manager, joins Yahoo Finance to discuss. ...
